Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
ROCKVILLE, Md., Feb. 02, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day. The conference will take place on Tuesday, February 14, 2017 at the JW Marriott Essex House New York in New York, NY. REGENXBIO representatives will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform Licensees. REGENXBIO and its licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Laura Bagby, 312-448-8098 [email protected]
